INMB Q1 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4,000

Gross Profit

$4,000100.0% margin

Operating Income

-$5M-113700.0% margin

Net Income

-$5M-113900.0% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-63.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$899,000

Balance Sheet

Total Assets

$66M

Total Liabilities

$2M

Stockholders' Equity

$64M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4,000	$0	—
Gross Profit	$4,000	$0	—
Operating Income	-$5M	-$2M	-117.4%
Net Income	-$5M	-$2M	-120.1%